THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, April 04, 2022
InMed’s THCV will bring ample opportunity for the health sector to scale up in the market.
FREMONT, CA: “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedicas growing product portfolio, stated Shane Johnson, MD, SVP and General Manager of BayMedica. THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike.”
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
InMed Pharmaceuticals, one of the leading companies in the research, development, manufacturing, and marketing of the scarce cannabinoid, unveiled B2B sales of delta 9-dominant tetrahydrocannabivarin into the drug market.
He further added, "In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product. As this market continues to mature, we are well-positioned to be a leading supplier of rare cannabinoids to the health and wellness industry. We currently have several high-value, rare cannabinoids in various stages of commercial development and will continue to expand our cannabinoid portfolio over the coming years.”
THCV molecules are slightly different in structure, which leads to various physiological effects. THCV is similar to intoxicating THC in name and structure but is found in low abundance, unlike THC. Crucial research shows the benefits of D-9 THCV in suppressing appetite and contributing highly to weight loss.
Marketing this product will benefit the health and wellness industry by providing consumers with differentiated products, including CBD products. This nascent market is likely to increase rapidly because of the growing knowledge of the significant gains of cannabinoid-based products.
More in News